Sign in

NIKI on Nasdaq

Niki BioSolutions, Inc.

Niki BioSolutions, Inc. is a measuring and controlling devices company in the Cayman Islands.1 It is headquartered in Princeton, New Jersey.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$1.4MNet income, fiscal 20252

Compare with Quantum-Si Inc, AUTOSCOPE TECHNOLOGIES CORP or Birchtech Corp., or pick any stock.

  • TickerNIKI on Nasdaq1
  • IndustryMeasuring & Controlling Devices, NEC1
  • HeadquartersPrinceton, New Jersey1
  • Incorporated inCayman Islands3
  • Business address116 Village Boulevard, Suite 200, Princeton, Nj 085403
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

October 13, 2017, ordinary resolutions were passed at an extraordinary general meeting of the Company approving (the “Conversions”):4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-654.8%Net margin2
-66.7%Revenue growth, 20232
-11.4%Return on equity5
-$7.7MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue7¢$420.8K
  • Research and development93¢$5.2M

Out of $431.4K in revenue.2 The company lost money this year.

Financial statements

Revenue652$431.4K in 2023−72% since 2021
0$500.0K$1.0M$1.5M$2.0M2021: $1.5M$1.5M20212022: $1.3M$1.3M2022−16%2023: $431.4K$431.4K2023−67%
Net income789652-$2.8M in 2023−81% since 2018
-$30.0M-$20.0M-$10.0M0$10.0M2018: -$14.8M-$14.8M20182019: -$20.1M-$20.1M2019+36%2020: $4.9M$4.9M20202021: -$25.0M-$25.0M20212022: -$9.8M-$9.8M2022−61%2023: -$2.8M-$2.8M2023−71%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Healthcare services income$431.4K
Cost of healthcare services-$420.8K
Research and development expenses-$352.9K-$2.2M-$5.2M
General and administrative fees-$573.1K-$669.5K-$1.9M
Legal and professional fees-$1.1M-$803.3K-$2.5M
Other operating income (expenses)$170.8K-$272.6K-$1.1M
Total operating expenses-$1.8M-$3.9M-$11.2M
Loss on investments in marketable securities, net-$9.3K
Unrealized gain from fair value change of the long-term investments, net$6.4M
Impairment loss of long-term investment-$1.0M-$77.2K
Interest expense, net-$95.7K-$146.9K-$121.1K
Gain on disposal of subsidiaries$703
Issuance cost allocated to warrant liability-$153.2K
Change in fair value of warrant liability$690.0K
Government subsidies$928.5K$123.0K
Sundry income$564$36.8K
Total other income (expense), net$441.1K-$217.2K$6.4M
Net loss-$1.4M-$4.2M-$4.3M
Net income (loss) attributable to non-controlling interests$13.2K-$110.1K$1.5M
Net loss attributable to Aptorum Group Limited-$1.4M-$4.3M-$2.8M
Basic (in Dollars per share)-$0.19-$0.78-$0.62
Diluted (in Dollars per share)-$0.19-$0.78-$0.62
Basic (in Shares)7.4M shares5.5M shares4.5M shares
Diluted (in Shares)7.4M shares5.5M shares4.5M shares
Exchange differences on translation of foreign operations-$181.5K$99.8K-$44.4K
Other comprehensive (loss) income-$181.5K$99.8K-$44.4K
Comprehensive loss-$1.6M-$4.1M-$4.4M
Comprehensive (loss) income attributable to non-controlling interests-$13.2K$110.1K-$1.5M
Comprehensive loss attributable to the shareholders of Aptorum Group Limited-$1.5M-$4.2M-$2.9M

Compare Niki BioSolutions, Inc. with another company

Corporate structure

Niki BioSolutions, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Niki BioSolutions, Inc.

  • Niki BioSolutions, Inc. Princeton, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Niki BioSolutions, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.8M2 Dec 31, 2025$4.8M2 Dec 31, 20240%
Accumulated depreciation$4.8M2 Dec 31, 2025$4.8M2 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.5M2 Dec 31, 2025$874.2K2 Dec 31, 2024+295.0%
Equity securities at fair value$4.1M2 Dec 31, 2025$4.1M2 Dec 31, 20240%
Long-term investments$15.1M2 Dec 31, 2025$15.1M2 Dec 31, 20240%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$423.9K2 Dec 31, 2025$423.9K2 Dec 31, 20240%
Accumulated amortization$423.9K2 Dec 31, 2025$423.9K2 Dec 31, 20240%

Leadership

Who has led Niki BioSolutions, Inc., and when. Pick a name to see everywhere that person has worked.

President

  1. Alidad Mireskandari2026–now

Chief operating officer

  1. Alidad Mireskandari2026–now
Board members and other officers (4)

Former names

  • Aptorum Group LtdMar 28, 2018 to Jun 22, 20263

Timeline

  1. Oct 13, 20268-K Executive or director change16
  2. Oct 9, 20268-K Entered a material agreement17
  3. Sep 14, 20268-K Other events18
  4. Sep 4, 20268-K Executive or director change19
  5. Aug 21, 20268-K Financial statements and exhibits20
  6. Aug 21, 20268-K Financial statements and exhibits21
  7. Aug 7, 20268-K Other events22
  8. Jul 20, 20268-K Completed an acquisition or sale; Change to shareholders' rights; Executive or director change23

Filings

133 filings to the SEC since October 2021: 6 annual reports, 8 major events, 5 insider forms, 8 large holders, 106 other. The latest 20:

  1. Oct 13, 20268-K CURRENT REPORT EDGAR
  2. Oct 9, 2026EFFECT EDGAR
  3. Oct 9, 20268-K CURRENT REPORT EDGAR
  4. Oct 9, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  5. Oct 2, 2026S-3/A PRE-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 EDGAR
  6. Sep 18, 2026S-3/A PRE-EFFECTIVE AMENDMENT 2 TO FORM S-3 EDGAR
  7. Sep 14, 20268-K CURRENT REPORT EDGAR
  8. Sep 4, 20268-K CURRENT REPORT EDGAR
  9. Aug 28, 2026RW WITHDRAWAL REQUEST EDGAR
  10. Aug 28, 2026S-3 REGISTRATION STATEMENT EDGAR
  11. Aug 21, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  12. Aug 21, 20268-K CURRENT REPORT EDGAR
  13. Aug 13, 20263 EDGAR
  14. Aug 13, 20263 EDGAR
  15. Aug 7, 20268-K CURRENT REPORT EDGAR
  16. Jul 28, 20263 EDGAR
  17. Jul 24, 2026SCHEDULE 13D EDGAR
  18. Jul 24, 20263 EDGAR
  19. Jul 24, 20263 EDGAR
  20. Jul 20, 20268-K CURRENT REPORT EDGAR

The 133 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Niki BioSolutions, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNiki BioSolutions, Inc.1
  • CIK0001734005
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3829 Measuring & Controlling Devices, NEC1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address116 Village Boulevard, Suite 200, Princeton, NJ 085401
  • Phone852 3953 77001
  • Shares outstanding6,346,823 Common Class A shares; 1,796,934 Common Class B shares as of Dec 31, 20254
  • AuditorMarcum Asia CPAs LLP, Guangzhou, China PCAOB ID 5395; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMar 28, 20181
  • Filings255 in all: 6-K (97), CORRESP (22), EFFECT (14), UPLOAD (14), F-1/A (10), 20-F (8), 424B5 (8), 6-K/A (7)1
    All 39 form types

    8-K (7), SC 13D/A (7), POS AM (6), 3 (5), F-1 (4), F-3 (4), S-4/A (4), 424B3 (3), 424B4 (3), DRS (3), SC 13D (3), 20-F/A (2), RW (2), S-3/A (2), S-8 (2), SC 13G (2), SCHEDULE 13G (2), 8-A12B (1), 8-K/A (1), CERT (1), CT ORDER (1), D (1), DEL AM (1), F-1MEF (1), FWP (1), S-3 (1), S-4 (1), S-8 POS (1), SC 13G/A (1), SCHEDULE 13D (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 27, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary shares, par value $0.00001APMNASDAQ

From the cover page of the 20-F filed Mar 27, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    SEC EDGAROther events
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28